Evidence map›Paper›PMID 41147981›Full record

ArticleBioconjugate chemistry2025

Far-Red Spray-On Imaging Probes for FAP-Targeted Cancer Surgery.

Zachary Rabinowitz, Riley J Deutsch-Williams, Ralph Weissleder

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Erasable FAP Targeted Spray-On Probe for Fluorescence-Guided Surgery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zachary RabinowitzCenter for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, Massachusetts 02114, United States.ORCID 0009-0002-1250-5164
Riley J Deutsch-WilliamsCenter for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, Massachusetts 02114, United States.
Ralph WeisslederCenter for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, Massachusetts 02114, United States.ORCID 0000-0003-0828-4143

Funding

Training Grant in Molecular Imaging Research (MGH/HMS)T32CA079443 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2000 to 2025
$10.1M
Temporal analysis of the GBM tumor microenvironment during myeloid cell activating therapyR01CA281735 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI RALPH WEISSLEDER, MD, PhD · 2023 to 2026
$2.3M
Bioorthogonal probe development for highly parallel in vivo imagingR33CA277820 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2023 to 2025
$1.2M
NCI NIH HHS R01 CA281735NCI NIH HHS R33 CA277820NCI NIH HHS T32 CA079443
6 · The paper itself

Abstract

Fluorescence-guided surgery (FGS) using fluorescent imaging probes is an emerging technology that enables tumor margin detection at potentially higher accuracy than is possible with traditional means. Most FGS imaging probes are administered systemically, many hours before a planned surgery, and must have cleared the bloodstream once surgery is initiated, so as not to contaminate the operative field. Topical administration of specially designed conjugates in the form of spray-on probes (SOP) offers the advantage of much lower doses, on-demand use, and result in far higher achievable image contrast. Here we report the discovery and characterization of a far-red SOP imaging agent targeting fibroblast activation protein alpha. We show that only 1 out of 10 synthesized probes has appropriate imaging and biological characteristics, increasing tumor-to-background ratio by 5-15 fold. The optimal SOP (FTF-Cy5) was able to delineate tumor margins rapidly (<10 min) when sprayed on at a low dose (5 μM) followed by a short washing step. These results suggest that the lead far-red SOP has the potential to be utilized as a spray-on intraoperative tumor margin delineation tool using far-red fluorescence imaging systems in the operating room, thereby simplifying surgical workflows and enabling more complete cancer resections in the future.

Indexed as

Fluorescent DyesMembrane ProteinsNeoplasmsOptical ImagingSerine EndopeptidasesSurgery, Computer-AssistedAnimalsCell Line, TumorEndopeptidasesFemaleFibroblast Activation Protein AlphaHumansMiceEndopeptidasesFibroblast Activation Protein AlphaFluorescent DyesMembrane ProteinsSerine Endopeptidases

Identifiers

PMID41147981
PMCPMC13449254

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.